Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Monk

Gynecologic Oncology West Palm Beach, FL Medical Doctor

NPI 1487734646 CMS profile 249435

1309 N Flagler Dr, West Palm Beach, FL 33401

Open in the dashboard

General payments

$2,540,708

1,903 records reported · program years 2019–2025

Research payments

$79,484

Paid to them · 51 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,930,570 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Bradley Monk of West Palm Beach, FL is reported in the CMS Open Payments database as having received $2,540,708 across 1,903 general payments and $79,484 in research payments paid to them. Separately, studies naming them as principal investigator received $7,930,570 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $306,026 246
2025 Research $2,063 3
2024 General $306,031 242
2024 Research $3,095 4
2023 General $329,222 213
2023 Research $143 1
2022 General $395,559 244
2022 Research $7,370 22
2021 General $344,037 224
2021 Research $66,072 10
2020 General $298,974 202
2020 Research $278 1
2019 General $560,859 532
2019 Research $463 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Monk
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Bradley Monk were reported at $306,026. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Bradley Monk Gynecologic Oncology median Middle half National median
2019 $560,859 $287 $113–$1,548 $163
2020 $298,974 $223 $59–$2,164 $114
2021 $344,037 $193 $68–$1,139 $132
2022 $395,559 $252 $90–$1,151 $149
2023 $329,222 $281 $102–$1,419 $160
2024 $306,031 $308 $108–$1,502 $164
2025 $306,026 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $674,121 358 payments
  2. AstraZeneca Pharmaceuticals LP $354,562 254 payments
  3. Merck Sharp & Dohme Corporation $332,090 305 payments
  4. Genmab U.S., Inc. $154,723 121 payments
  5. TESARO, Inc. $144,438 165 payments
  6. Seattle Genetics, Inc. $112,467 89 payments
  7. Clovis Oncology, Inc. $90,130 88 payments
  8. Myriad Genetic Laboratories, Inc. $82,235 72 payments
  9. Eisai Inc. $78,317 77 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $76,974 13 payments
  11. Other $440,652 361 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,140,656 294 payments
  2. Consulting Fee $914,748 301 payments
  3. Travel and Lodging $397,218 640 payments
  4. Honoraria $46,343 17 payments
  5. Food and Beverage $40,479 645 payments
  6. Grant $1,078 2 payments
  7. Education $185 4 payments
Products named General payments · program years 2019–2025
  1. LYNPARZA $318,612 218 payments
  2. ZEJULA Oncology $305,792 290 payments
  3. ZEJULA Oncology $133,131 100 payments
  4. TIVDAK Oncology $122,037 93 payments
  5. TIVDAK Oncology $116,358 80 payments
  6. JEMPERLI $115,920 79 payments
  7. Rubraca $86,344 70 payments
  8. KEYTRUDA $84,323 120 payments
  9. Lenvima $80,976 77 payments
  10. ELAHERE $49,007 42 payments
  11. Other $350,585 414 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $64,386 2 payments
  2. Regeneron Pharmaceuticals, Inc. $11,467 35 payments
  3. Pfizer Inc. $1,600 3 payments
  4. F. Hoffmann-La Roche AG $1,340 1 payment
  5. Novartis Pharma AG $346 1 payment
  6. Seattle Genetics, Inc. $345 9 payments

Records

1,954 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record